NeuroHealing Announces Strategic Master Services and Investment Agreement with Cato BioVentures

Newton, Massachusetts – May 16, 2011. NeuroHealing Pharmaceuticals today announced that it has entered into a strategic master services and investment agreement with Cato BioVentures. This agreement includes a collaboration with Cato Research Ltd. (“Cato”), its global contract research organization, to assist in the clinical development of NeuroHealing’s lead drug NH001. The investment and collaboration…